Spyre Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Spyre Therapeutics, Inc. (SYRE) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-208.02-338.79-83.82-65.80-80.89-78.25-44.35
Depreciation & Amortization0.000.961.962.121.00-0.420.29
Stock Based Compensation44.8325.687.118.046.260.000.00
Change in Working Capital-4.53-2.88-5.502.24-2.547.367.20
Change in Accounts Receivable0.000.380.44-0.820.000.000.00
Change in Accounts Payable-0.23-2.18-2.641.07-0.540.000.00
Change in Other Working Capital-4.30-3.970.43-1.99-2.000.000.00
Other Operating Activities10.31153.810.437.720.335.600.07
Net Cash from Operating Activities-157.41-99.91-80.14-53.72-75.78-65.71-32.19
Investing Activities
Capital Expenditures0.000.48-0.040.57-4.281.49-0.42
Acquisitions0.003.040.000.000.000.000.00
Purchases of Investments-599.25-126.90-39.50-22.05-3.320.000.00
Sales/Maturities of Investments245.97-126.9096.55-22.05-3.32-0.25-14.81
Net Cash from Investing Activities-353.29-108.3957.01-22.62-7.60-1.74-15.23
Financing Activities
Debt Repayment0.00-0.02-0.42-0.51-0.02-0.030.00
Common Stock Issued236.38169.1142.871.90154.530.0054.05
Other Financing Activities174.52-5.7942.870.00153.7264.300.00
Net Cash from Financing Activities410.91361.0842.681.39154.5165.7257.07
Summary
Effect of Forex Changes on Cash0.000.03-0.11-0.020.050.000.00
Net Change in Cash-99.79152.8019.54-74.9471.18-1.739.64
Cash at Beginning of Period189.2236.4216.9891.9420.7522.4612.82
Cash at End of Period89.42-316.2236.4291.9491.9420.7422.46
Free Cash Flow-157.41-84.44-80.18-54.29-80.06-67.20-32.62